Drug intelligence / Profile preview

SOL-804-F

Development stage: Phase 1
Lead developer: Dyna Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SOL-804-F is an improved and proprietary formulated version of abiraterone acetate for the treatment of metastatic castration-resistant prostate cancer. It utilizes the drug delivery platform 'Lymphatic Targeting Technology™' which aims to mitigate the impact of food intake on drug absorption and reduce side effects through low-dose administration. Unlike existing treatments that require administration at least 2 hours after a meal and prohibit food intake for at least 1 hour post-dose, SOL-804-F is designed to improve patient convenience and compliance.

Targets

CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)

Beyond the preview

Go deeper on SOL-804-F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-804-F.

Explore the full profile